Cargando…
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025269/ https://www.ncbi.nlm.nih.gov/pubmed/32474843 http://dx.doi.org/10.1007/s10637-020-00949-8 |
| _version_ | 1783675464583217152 |
|---|---|
| author | Kroschinsky, Frank Middeke, Jan Moritz Janz, Martin Lenz, Georg Witzens-Harig, Mathias Bouabdallah, Reda La Rosée, Paul Viardot, Andreas Salles, Gilles Kim, Seok Jin Kim, Tae Min Ottmann, Oliver Chromik, Joerg Quinson, Anne-Marie von Wangenheim, Ute Burkard, Ute Berk, Andreas Schmitz, Norbert |
| author_facet | Kroschinsky, Frank Middeke, Jan Moritz Janz, Martin Lenz, Georg Witzens-Harig, Mathias Bouabdallah, Reda La Rosée, Paul Viardot, Andreas Salles, Gilles Kim, Seok Jin Kim, Tae Min Ottmann, Oliver Chromik, Joerg Quinson, Anne-Marie von Wangenheim, Ute Burkard, Ute Berk, Andreas Schmitz, Norbert |
| author_sort | Kroschinsky, Frank |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8025269 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80252692021-04-26 Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma Kroschinsky, Frank Middeke, Jan Moritz Janz, Martin Lenz, Georg Witzens-Harig, Mathias Bouabdallah, Reda La Rosée, Paul Viardot, Andreas Salles, Gilles Kim, Seok Jin Kim, Tae Min Ottmann, Oliver Chromik, Joerg Quinson, Anne-Marie von Wangenheim, Ute Burkard, Ute Berk, Andreas Schmitz, Norbert Invest New Drugs Correction Springer US 2020-05-31 2021 /pmc/articles/PMC8025269/ /pubmed/32474843 http://dx.doi.org/10.1007/s10637-020-00949-8 Text en © Springer Science+Business Media, LLC, part of Springer Nature 2020 https://creativecommons.org/licenses/by/4.0/ This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Correction Kroschinsky, Frank Middeke, Jan Moritz Janz, Martin Lenz, Georg Witzens-Harig, Mathias Bouabdallah, Reda La Rosée, Paul Viardot, Andreas Salles, Gilles Kim, Seok Jin Kim, Tae Min Ottmann, Oliver Chromik, Joerg Quinson, Anne-Marie von Wangenheim, Ute Burkard, Ute Berk, Andreas Schmitz, Norbert Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma |
| title | Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma |
| title_full | Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma |
| title_fullStr | Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma |
| title_full_unstemmed | Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma |
| title_short | Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma |
| title_sort | correction to: phase i dose escalation study of bi 836826 (cd37 antibody) in patients with relapsed or refractory b-cell non-hodgkin lymphoma |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025269/ https://www.ncbi.nlm.nih.gov/pubmed/32474843 http://dx.doi.org/10.1007/s10637-020-00949-8 |
| work_keys_str_mv | AT kroschinskyfrank correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT middekejanmoritz correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT janzmartin correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT lenzgeorg correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT witzensharigmathias correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT bouabdallahreda correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT laroseepaul correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT viardotandreas correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT sallesgilles correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT kimseokjin correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT kimtaemin correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT ottmannoliver correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT chromikjoerg correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT quinsonannemarie correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT vonwangenheimute correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT burkardute correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT berkandreas correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT schmitznorbert correctiontophaseidoseescalationstudyofbi836826cd37antibodyinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma |